Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. junior Avg
|
New words:
abrogated, affinity, amplification, Antengene, appealing, aspire, ATR, Atrin, ATRIZE, AUC, bankruptcy, BB, beagle, bid, Bioeconomy, Biomanufacturing, biomarker, broaden, built, bulleted, career, Catalyst, CDX, cessation, closure, collapse, colon, commodity, conformationally, Connecticut, counterparty, curve, customer, CVR, cyclin, cyclization, DDR, Debiopharm, default, delisted, delisting, deposit, differentiated, differentiating, discretionary, disfavor, dissimilar, division, double, Doylestown, driven, DSB, Easton, editing, effectuated, Eleventh, endonuclease, engineering, enrich, entirety, Exhibit, exhibited, exploratory, fashion, FDIC, female, field, flexible, forgoing, fourth, fractional, freedom, fulfill, fundamental, geopolitical, Gilad, grew, grow, Hamill, hemoglobin, hereto, ideal, incidental, inflation, insolvency, insolvent, intermittent, invasion, IRA, irreparable, issuable, John, leader, Leerink, legacy, lending, lethal, lethality, leveraging, liver, Lynparza, machine, macrocycle, macrocyclic, macroeconomic, magnify, magnitude, male, mammalian, metabolite, military, mM, mTOR, nearest, negligent, negligible, nM, NME, noncompliance, null, olaparib, oncogenic, opposed, Oren, OTC, outpace, overexpression, Overview, pair, Pamiparib, paradigm, PARP, PARPi, payroll, PDUFA, PDX, penalize, Pennsylvania, Pharma, phenomenon, phosphatidylinositol, phosphorylation, PIKK, pink, PLK, poly, polymerase, potent, prominently, proteomic, QB, quotation, rapamycin, ratification, rationally, receivership, recombination, red, Repare, resale, Rescue, risky, Road, rounded, Rubraca, Russian, SBIR, SCET, Schrodinger, Serono, shifted, shifting, Signature, Silicon, Silvergate, skilled, smooth, SMX, sophisticated, spectrum, speculative, strand, subcutaneously, supplier, SVB, swept, Talzenna, tangible, telangiectasia, text, thereunder, tighter, true, tying, Ukraine, unblinded, unchanged, underway, underwritten, undrawn, uninsured, unusual, unvested, Utah, Valley, vehicle, wage, window, wrap, Zejula
Removed:
AACR, abbvie, abdominal, abnormal, Abrahmsen, accumulation, achieved, acid, acute, additive, adult, affix, Africa, age, aggressive, Aileron, al, allogeneic, Altor, Amgen, amino, analog, antecedent, antibody, apoptotic, appetite, approvable, argenx, arm, Astex, attained, Attar, Australia, Austria, authorisation, BCR, Belgium, belong, benchmark, binding, biology, biopharma, Bioscience, biotech, biotechnological, blast, bleeding, blockade, bone, Boylston, Brazil, Bruton, BTK, Bulgaria, cascade, CDG, CE, chemotherapeutic, CHMP, Christian, chromosomal, chromosome, clause, cleared, clock, Coiante, coincident, Commun, competent, complied, comprising, confirmed, conformation, contemporaneously, coordination, copy, counteract, covalent, CRi, crystal, CTI, curative, customary, cutoff, Cyclacel, cytogenetic, Czech, Dacogen, Daiichi, de, decentralized, decitabine, declaration, dedicated, Denmark, diagnosed, diagram, died, directing, Directive, Dis, discriminate, disorder, distinction, divided, donor, dossier, driver, dysfunctional, dyspnea, EC, Eisai, elaborate, embolism, enhancing, ensured, entitling, erected, Estonia, evaluable, exert, experimental, explained, explicit, explored, extra, Eyal, fate, feature, FGFR, fill, Finland, fix, fluoropyrimidine, folded, formulated, functionally, FY, gastroesophageal, gathering, Germany, Ghosh, Gilead, glutaredoxin, glutathione, GmbH, GMP, Greece, GSH, guaranteed, guardian, Haffo, hallmark, Hameln, harmonized, headache, heightened, hematopoietic, highest, Historically, HMA, Hoffman, Hong, hotspot, HTA, humanized, Hungary, hypomethylating, Iceland, illiquid, immature, immunomodulatory, imposing, incompetent, Incyte, India, indirect, induction, injection, intense, intensive, interval, intervention, intracellular, intravenously, intrinsic, involvement, ipilimumab, irinotecan, Israel, Italy, Japan, Johnson, junction, Juno, justified, Karyopharm, karyotype, Kettering, Kong, Korea, La, Latvia, Lithuania, Liu, locally, Luxembourg, lymphocytic, lymphoma, main, malignant, Malta, Marino, mark, markedly, marrow, mcl, median, MedVax, Memorial, men, metastatic, Milennium, missense, Monaco, monoclonal, MQ, mutational, Nat, necessity, NHL, nivolumab, noncancelable, Norway, novo, older, oncologic, oncological, Onconova, Ono, opened, ORR, OS, oxidase, oxidative, oxygen, packing, pain, partly, pembrolizumab, Peng, Perdrix, peripheral, Pfizer, pharmacoeconomic, phenotype, PIP, platinum, player, PMA, PMV, point, Poland, poor, Portugal, predictable, predominantly, premarket, prognostic, progressive, proliferating, provisional, purified, QSR, radiological, ramucirumab, randomized, reactivated, reactivating, reactive, real, RECIST, recurrent, redox, reductase, referencing, reinforce, relapse, reproducible, Republic, respiratory, restore, revert, revoked, RFS, ribonucleotide, RNR, Roche, Romania, ROS, Sallman, San, Sankyo, SAS, Schade, scheduled, Sci, Scott, segmented, selecting, senescence, Senhwa, sense, sequencing, Servier, shipping, Siegfried, simplify, simply, simultaneously, Singapore, Sloan, Slovakia, Slovenia, South, Spain, spare, Squibb, stabilization, stem, step, sterile, Stockholm, stomach, streamline, streamlined, strongest, structural, subset, subtype, suffering, sunset, suppression, suppressive, syndrome, synergistic, Syngene, Taiwanese, Takeda, TG, Thailand, thioredoxin, tied, topoisomerase, traceability, transparent, transplant, transplantation, Turkey, tyrosine, unlimited, unscheduled, untreated, upregulation, upstream, validated, vast, Vidaza, viewpoint, vivo, wild, women, worse
Filing tables
Filing exhibits
- 10-K Annual report
- 4.1 EX-4.1
- 10.9 EX-10.9
- 10.10 EX-10.10
- 10.11 EX-10.11
- 10.13 EX-10.13
- 10.15 EX-10.15
- 10.16 EX-10.16
- 10.18 EX-10.18
- 10.19 EX-10.19
- 10.20 EX-10.20
- 10.21 EX-10.21
- 21.1 EX-21.1
- 23.1 EX-23.1
- 23.2 EX-23.2
- 31.1 EX-31.1
- 31.2 EX-31.2
- 32.1 EX-32.1
- 32.2 EX-32.2
- Download Excel data file
- View Excel data file
Related press release
APRE similar filings
Filing view
External links
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the following Registration Statements:
(1) | Registration Statement (Form S-8 No. 333-234765) pertaining to the 2019 Equity Incentive Plan of Aprea Therapeutics, Inc., |
(2) | Registration Statement (Form S-8 No. 333-250043) pertaining to the 2019 Equity Incentive Plan of Aprea Therapeutics, Inc., |
(3) | Registration Statement (Form S-3/A No. 333-250041) of Aprea Therapeutics, Inc., |
(4) | Registration Statement (Form S-8 No. 333-260884) pertaining to the 2019 Equity Incentive Plan of Aprea Therapeutics, Inc., |
(5) | Registration Statement (Form S-8 No. 333-268816) pertaining to the 2019 Equity Incentive Plan of Aprea Therapeutics, Inc., |
(6) | Registration Statement (Form S-8 No. 333-265411) pertaining to the Atrin Pharmaceuticals LLC 2016 Amended and Restated Equity Compensation Plan, |
of our report dated March 30, 2023, with respect to the consolidated financial statements of Aprea Therapeutics, Inc. included in this Annual Report (Form 10-K) for the year ended December 31, 2022.
/s/ Ernst & Young LLP
Iselin, New Jersey
March 30, 2023